SOLANA BEACH, Calif. — October 7, 2026
Artelo Biosciences announced that it has been selected to deliver its first-ever company presentation at BIO-Europe 2026, taking place November 9–11 in Cologne, Germany. The presentation, scheduled for November 10, will highlight clinical progress for ART26.12, Artelo’s lead fatty acid binding protein 5 (FABP5) inhibitor, and the broader potential of the company’s lipid-signaling platform. Artelo said the event will also provide an opportunity to advance business development and partnering discussions across its clinical-stage and earlier-stage portfolio, particularly in pain and inflammation. Senior Vice President and Chief Scientific Officer Andrew Yates, Ph.D., will present the company’s pipeline and meet with pharmaceutical and biotechnology organizations during the conference.
ART26.12 Clinical Data Support Further Development
The BIO-Europe presentation will feature results from the first clinical study of ART26.12, a selective FABP5 inhibitor being developed as a peripherally acting, non-opioid and non-steroidal analgesic. In a Phase 1 single ascending dose study in healthy volunteers, ART26.12 demonstrated a favorable safety and tolerability profile across evaluated cohorts, together with linear and dose-proportional pharmacokinetics. Separately reported human metabolite findings indicated favorable drug metabolism characteristics. Preliminary food-effect data also showed that ART26.12 could be administered under fasted and fed conditions, including low-fat and high-fat meals, supporting potential flexibility in dosing approaches as the program advances across different indications.
FABP5 Inhibition Targets Pain and Neuropathy
Artelo is developing ART26.12 initially for chemotherapy-induced peripheral neuropathy (CIPN), while evaluating broader applications in pain and inflammation. Across five nonclinical studies, the compound demonstrated potential activity against painful neuropathies associated with diabetes and chemotherapy and showed potential to prevent neuropathy when administered alongside paclitaxel or oxaliplatin. In a separate nonclinical osteoarthritis study, oral ART26.12 significantly reduced pain associated with osteoarthritis over four weeks, with an effect reported to be comparable to naproxen. The study also identified changes in endocannabinoids and related bioactive lipids and proteins, supporting a differentiated mechanism of action. Artelo reported less stomach tissue damage in animals treated with ART26.12 compared with those receiving naproxen.
Advertisement
Artelo Expands Partnering Opportunities at BIO-Europe
Artelo plans to use BIO-Europe 2026 to expand discussions with potential pharmaceutical and biotechnology partners across its portfolio. The company said its growing development platform includes programs addressing pain, cancer cachexia, obesity and other conditions involving lipid-signaling pathways. The company’s FABP inhibitor library has also shown preclinical promise across cancer, neuropathic and nociceptive pain, psoriasis and anxiety disorders. The BIO-Europe presentation comes after multiple clinical and nonclinical milestones for ART26.12 and is intended to communicate both the compound’s clinical progress and the broader potential of selective FABP5 inhibition. Artelo said its participation will support ongoing evaluation of partnering opportunities as it advances ART26.12 and other assets toward further development.
Source::Artelo Biosciences press release
